Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway

Allergic asthma is one of the most common chronic airway diseases, and there is still a lack of effective drugs for the treatment of allergic asthma. The purpose of this work is to formulate rhynchophylline (Rhy)-solid lipid nanoparticles (SLNs) to improve their therapeutic efficacy in a mice allerg...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chuanfeng Lv, Hui Li, Hongxia Cui, Qianyu Bi, Meng Wang
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	rhynchophylline solid lipid nanoparticle allergic asthma suppressor of cytokine signaling 1 p38 signaling pathway Biotechnology TP248.13-248.65
Acceso en línea:	https://doaj.org/article/d216f51b4fa2462083b67359b31e7e65
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d216f51b4fa2462083b67359b31e7e65
record_format	dspace
spelling	oai:doaj.org-article:d216f51b4fa2462083b67359b31e7e652021-11-04T15:51:53ZSolid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway2165-59792165-598710.1080/21655979.2021.1988364https://doaj.org/article/d216f51b4fa2462083b67359b31e7e652021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/21655979.2021.1988364https://doaj.org/toc/2165-5979https://doaj.org/toc/2165-5987Allergic asthma is one of the most common chronic airway diseases, and there is still a lack of effective drugs for the treatment of allergic asthma. The purpose of this work is to formulate rhynchophylline (Rhy)-solid lipid nanoparticles (SLNs) to improve their therapeutic efficacy in a mice allergic model of asthma. A solvent injection method was employed to prepare the Rhy-SLNs. Physicochemical characterization of Rhy-SLNs was measured, and the release assessment was investigated, followed by the release kinetics. Next, a model of murine experimental asthma was established. Mice were subcutaneously injected with 20 μg ovalbumin mixed with 1 mg aluminum hydroxide on days 0, 14, 28, and 42 and administrated aerosolized 1% ovalbumin (w/v) by inhalation from day 21 to day 42. Mice were intraperitoneally injected with 20 mg/kg Rhy-SLNs or Rhy at one hour before the airway challenge with ovalbumin. The results showed that Rhy-SLNs revealed a mean particle size of 62.06 ± 1.62 nm with a zeta potential value of −6.53 ± 0.04 mV and 82.6 ± 1.8% drug entrapment efficiency. The release curve of Rhy-SLNs was much higher than the drug released in phosphate buffer saline at 0, 1, 1.5, 2, 4, or 6 h. Moreover, Rhy-SLNs exerted better effects on inhibiting ovalbumin-induced airway inflammation, oxidative stress, airway remodeling (including collagen deposition and mucus gland hyperplasia) than Rhy in murine experimental asthma. Subsequently, we found that Rhy-SLNs relieved allergic asthma via the upregulation of the suppressor of cytokine signaling 1 by repressing the p38 signaling pathway.Chuanfeng LvHui LiHongxia CuiQianyu BiMeng WangTaylor & Francis Grouparticlerhynchophyllinesolid lipid nanoparticleallergic asthmasuppressor of cytokine signaling 1p38 signaling pathwayBiotechnologyTP248.13-248.65ENBioengineered, Vol 12, Iss 1, Pp 8635-8649 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	rhynchophylline solid lipid nanoparticle allergic asthma suppressor of cytokine signaling 1 p38 signaling pathway Biotechnology TP248.13-248.65
spellingShingle	rhynchophylline solid lipid nanoparticle allergic asthma suppressor of cytokine signaling 1 p38 signaling pathway Biotechnology TP248.13-248.65 Chuanfeng Lv Hui Li Hongxia Cui Qianyu Bi Meng Wang Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway
description	Allergic asthma is one of the most common chronic airway diseases, and there is still a lack of effective drugs for the treatment of allergic asthma. The purpose of this work is to formulate rhynchophylline (Rhy)-solid lipid nanoparticles (SLNs) to improve their therapeutic efficacy in a mice allergic model of asthma. A solvent injection method was employed to prepare the Rhy-SLNs. Physicochemical characterization of Rhy-SLNs was measured, and the release assessment was investigated, followed by the release kinetics. Next, a model of murine experimental asthma was established. Mice were subcutaneously injected with 20 μg ovalbumin mixed with 1 mg aluminum hydroxide on days 0, 14, 28, and 42 and administrated aerosolized 1% ovalbumin (w/v) by inhalation from day 21 to day 42. Mice were intraperitoneally injected with 20 mg/kg Rhy-SLNs or Rhy at one hour before the airway challenge with ovalbumin. The results showed that Rhy-SLNs revealed a mean particle size of 62.06 ± 1.62 nm with a zeta potential value of −6.53 ± 0.04 mV and 82.6 ± 1.8% drug entrapment efficiency. The release curve of Rhy-SLNs was much higher than the drug released in phosphate buffer saline at 0, 1, 1.5, 2, 4, or 6 h. Moreover, Rhy-SLNs exerted better effects on inhibiting ovalbumin-induced airway inflammation, oxidative stress, airway remodeling (including collagen deposition and mucus gland hyperplasia) than Rhy in murine experimental asthma. Subsequently, we found that Rhy-SLNs relieved allergic asthma via the upregulation of the suppressor of cytokine signaling 1 by repressing the p38 signaling pathway.
format	article
author	Chuanfeng Lv Hui Li Hongxia Cui Qianyu Bi Meng Wang
author_facet	Chuanfeng Lv Hui Li Hongxia Cui Qianyu Bi Meng Wang
author_sort	Chuanfeng Lv
title	Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway
title_short	Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway
title_full	Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway
title_fullStr	Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway
title_full_unstemmed	Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway
title_sort	solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/d216f51b4fa2462083b67359b31e7e65
work_keys_str_mv	AT chuanfenglv solidlipidnanoparticledeliveryofrhynchophyllineenhancedtheefficiencyofallergicasthmatreatmentviatheupregulationofsuppressorofcytokinesignaling1byrepressingthep38signalingpathway AT huili solidlipidnanoparticledeliveryofrhynchophyllineenhancedtheefficiencyofallergicasthmatreatmentviatheupregulationofsuppressorofcytokinesignaling1byrepressingthep38signalingpathway AT hongxiacui solidlipidnanoparticledeliveryofrhynchophyllineenhancedtheefficiencyofallergicasthmatreatmentviatheupregulationofsuppressorofcytokinesignaling1byrepressingthep38signalingpathway AT qianyubi solidlipidnanoparticledeliveryofrhynchophyllineenhancedtheefficiencyofallergicasthmatreatmentviatheupregulationofsuppressorofcytokinesignaling1byrepressingthep38signalingpathway AT mengwang solidlipidnanoparticledeliveryofrhynchophyllineenhancedtheefficiencyofallergicasthmatreatmentviatheupregulationofsuppressorofcytokinesignaling1byrepressingthep38signalingpathway
_version_	1718444741055479808

Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway

Ejemplares similares